<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04238819</url>
  </required_header>
  <id_info>
    <org_study_id>16950</org_study_id>
    <secondary_id>I3Y-MC-JPCS</secondary_id>
    <secondary_id>2019-002931-27</secondary_id>
    <nct_id>NCT04238819</nct_id>
  </id_info>
  <brief_title>A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors</brief_title>
  <official_title>A Phase 1b Dose Escalation Study of Abemaciclib in Combination With Temozolomide and Irinotecan (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study's purpose is to see if the drug abemaciclib is safe and effective in combination&#xD;
      with temozolomide and irinotecan (Part A) and abemaciclib in combination with temozolomide&#xD;
      (Part B) in pediatric and young adult participants with relapsed/refractory solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Anticipated">December 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number or Participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (21 Day Cycle)</time_frame>
    <description>Number of Participants with DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Mean Steady State Concentrations of Abemaciclib</measure>
    <time_frame>Cycle 1 through Cycle 3 (21 Day Cycle)</time_frame>
    <description>PK: Mean Steady State Concentrations of Abemaciclib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Mean Steady State Concentrations of Irinotecan</measure>
    <time_frame>Cycle 1 through Cycle 3 (21 Day Cycle)</time_frame>
    <description>PK: Mean Steady State Concentrations of Irinotecan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Mean Steady State Concentrations of Temozolomide</measure>
    <time_frame>Cycle 1 through Cycle 3 (21 Day Cycle)</time_frame>
    <description>PK: Mean Steady State Concentrations of Temozolomide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR): Percentage of Participants with Best Response of Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline through Disease Progression or Death (Estimated up to 24 Months)</time_frame>
    <description>ORR: Percentage of Participants with Best Response of CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Date of First Evidence of a CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 24 Months)</time_frame>
    <description>DoR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR): Percentage of Participants With Best Overall Response of CR, PR or SD With a Duration of At Least 6 Months</measure>
    <time_frame>Baseline through Disease Progression or Death Due to Any Cause (Estimated up to 24 Months)</time_frame>
    <description>CBR: Percentage of Participants With Best Overall Response of CR, PR or SD With a Duration of At Least 6 Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR): Percentage of Participants with a Best Overall Response of CR, PR, and Stable Disease (SD)</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 24 Months)</time_frame>
    <description>DCR: Percentage of Participants with a Best Overall Response of CR, PR, and SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability Questionnaire</measure>
    <time_frame>Cycle 2 Day 1 (21 Day Cycles)</time_frame>
    <description>Participants were evaluated for abemaciclib acceptability (palatability and ease of administration) using a 5-category questionnaire. Participants were asked to answer one of the following to describe the acceptability of abemaciclib: Very difficult, difficult, neither easy nor difficult, easy, or very easy.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Relapsed Solid Tumor</condition>
  <condition>Refractory Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Dose Escalation: Abemaciclib + Irinotecan + Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abemaciclib given orally, irinotecan given intravenously (IV) and temozolomide given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Abemaciclib + Irinotecan + Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abemaciclib given orally, irinotecan given IV and temozolomide given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation: Abemaciclib + Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abemaciclib and temozolomide given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Abemaciclib + Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abemaciclib and temozolomide given orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Dose Escalation: Abemaciclib + Irinotecan + Temozolomide</arm_group_label>
    <arm_group_label>Dose Escalation: Abemaciclib + Temozolomide</arm_group_label>
    <arm_group_label>Dose Expansion: Abemaciclib + Irinotecan + Temozolomide</arm_group_label>
    <arm_group_label>Dose Expansion: Abemaciclib + Temozolomide</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Dose Escalation: Abemaciclib + Irinotecan + Temozolomide</arm_group_label>
    <arm_group_label>Dose Expansion: Abemaciclib + Irinotecan + Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Dose Escalation: Abemaciclib + Irinotecan + Temozolomide</arm_group_label>
    <arm_group_label>Dose Escalation: Abemaciclib + Temozolomide</arm_group_label>
    <arm_group_label>Dose Expansion: Abemaciclib + Irinotecan + Temozolomide</arm_group_label>
    <arm_group_label>Dose Expansion: Abemaciclib + Temozolomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body weight ≥10 kilograms and body surface area (BSA) ≥0.5 meters squared.&#xD;
&#xD;
          -  Participants with any relapsed/refractory malignant solid tumor (excluding lymphoma),&#xD;
             including central nervous system tumors, that have progressed on standard therapies&#xD;
             and, in the judgment of the investigator, are appropriate candidates for the&#xD;
             experimental therapy combination in the study part that is currently enrolling.&#xD;
&#xD;
               -  Participants must have at least one measurable (per Response Criteria in Solid&#xD;
                  Tumors [RECIST v1.1; [Eisenhauer et al. 2009] or Response Assessment in&#xD;
                  Neuro-Oncology (RANO) for central nervous system (CNS) tumors [Wen et al. 2010])&#xD;
                  or evaluable lesion.&#xD;
&#xD;
               -  Participants must have had histologic verification of malignancy at original&#xD;
                  diagnosis or relapse, except:&#xD;
&#xD;
                    -  Participants with extra-cranial germ-cell tumors who have elevations of&#xD;
                       serum tumor markers including alpha-fetoprotein or beta- human chorionic&#xD;
                       gonadotropin (HCG).&#xD;
&#xD;
                    -  Participants with intrinsic brain stem tumors or participants with CNS-germ&#xD;
                       cell tumors and elevations of CSF or serum tumor markers including&#xD;
                       alpha-fetoprotein or beta-HCG.&#xD;
&#xD;
          -  A Lansky score ≥50 for participants ≤16 years of age or Karnofsky score ≥50 for&#xD;
             participants &gt;16 years of age.&#xD;
&#xD;
          -  Participants must have discontinued all previous treatments for cancer or&#xD;
             investigational agents and must have recovered from the acute effects to Grade ≤1 at&#xD;
             the time of enrollment.&#xD;
&#xD;
          -  Able to swallow.&#xD;
&#xD;
          -  Adequate hematologic and organ function ≤2 weeks (14 days) prior to first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Females of reproductive potential must have negative serum pregnancy test at baseline&#xD;
             (within 7 days prior to starting treatment).&#xD;
&#xD;
          -  Both female and male participants of reproductive potential must agree to use highly&#xD;
             effective contraceptive precautions (and avoid sperm donation for males) during the&#xD;
             trial. For abemaciclib, females should use contraception for at least 3 weeks&#xD;
             following the last abemaciclib dose (males have no restriction for contraceptive use&#xD;
             following treatment with abemaciclib). For other study drugs, highly effective&#xD;
             contraceptive precautions (and avoiding sperm donation) must be used according to&#xD;
             their label.&#xD;
&#xD;
          -  Life expectancy of at least 8 weeks and able to complete at least 1 cycle of&#xD;
             treatment.&#xD;
&#xD;
          -  Caregivers and participants willing to make themselves available for the duration of&#xD;
             the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received allogenic bone marrow or solid organ transplant.&#xD;
&#xD;
          -  Received live vaccination (within 4 weeks prior to starting study treatment).&#xD;
&#xD;
          -  Have a personal history of any of the following conditions within the last 12 months:&#xD;
             syncope of cardiovascular etiology, ventricular tachycardia, ventricular fibrillation,&#xD;
             or sudden cardiac arrest.&#xD;
&#xD;
          -  Intolerability or hypersensitivity to any of the study treatments or its components.&#xD;
&#xD;
          -  Diagnosed and/or treated additional malignancy within 3 years prior to enrollment that&#xD;
             may affect the interpretation of results, with the exception of curatively treated&#xD;
             basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or&#xD;
             curatively resected in situ cervical and/or breast cancers.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Active systemic infections or viral load.&#xD;
&#xD;
          -  Serious and/or uncontrolled preexisting medical condition(s) that would preclude&#xD;
             participation in this study.&#xD;
&#xD;
          -  Have a bowel obstruction (Part A of this study only).&#xD;
&#xD;
          -  Treated with drugs known to be strong inhibitors or inducers of isoenzyme cytochrome&#xD;
             P450 3A (CYP3A) or strong inhibitors of uridine diphosphate-glucuronosyl transferase&#xD;
             1A1 (UGT1A1) if the treatment cannot be discontinued or switched to a different&#xD;
             medication at least 5 half-lives prior to starting study drug.&#xD;
&#xD;
          -  Received prior treatment with cyclin-dependent kinase (CDK) 4 &amp; 6 inhibitor.&#xD;
&#xD;
          -  Currently enrolled in any other clinical study involving an investigational product or&#xD;
             non-approved use of a drug or device.&#xD;
&#xD;
          -  Has received an experimental treatment in a clinical trial within the last 30 days or&#xD;
             5 half-lives, whichever is longer.&#xD;
&#xD;
          -  Tumor contains known somatic or germline retinoblastoma (RB) mutation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>Clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>602-406-2141</phone>
    </contact>
    <investigator>
      <last_name>Lindsey M Hoffman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>612-626-3593</phone>
    </contact>
    <investigator>
      <last_name>Emily Greengard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>267-426-5414</phone>
    </contact>
    <investigator>
      <last_name>Frank M Balis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ-Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>003293324812</phone>
    </contact>
    <investigator>
      <last_name>Bram De Wilde</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <state>Rhône</state>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0033469166550</phone>
    </contact>
    <investigator>
      <last_name>Pierre LEBLOND</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00330144324270</phone>
    </contact>
    <investigator>
      <last_name>Isabelle Aerts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0033142114661</phone>
    </contact>
    <investigator>
      <last_name>Birgit Geoerger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>004930450666658</phone>
    </contact>
    <investigator>
      <last_name>Johannes Schulte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universtitätsklinikum Essen AöR</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00492017233784</phone>
    </contact>
    <investigator>
      <last_name>Dirk Reinhardt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopp-Kindertumorzentrum Heidelberg (KiTZ)</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00496221424585</phone>
    </contact>
    <investigator>
      <last_name>Kristian Pajtler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Gemelli - Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00390630155556</phone>
    </contact>
    <investigator>
      <last_name>Antonio Ruggiero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Chitose Ogawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Niño Jesús</name>
      <address>
        <city>Madrid</city>
        <state>Madrid, Comunidad De</state>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0034915035900</phone>
    </contact>
    <investigator>
      <last_name>Álvaro Lassaletta Atienza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0034934893093</phone>
    </contact>
    <investigator>
      <last_name>Lucas Moreno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0034961244000</phone>
    </contact>
    <investigator>
      <last_name>Antonio Juan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/7ojiQLuIsQzitz0DkvlAbe</url>
    <description>A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors</description>
  </link>
  <verification_date>November 1, 2021</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CDK4</keyword>
  <keyword>CDK6</keyword>
  <keyword>Ewing's sarcoma</keyword>
  <keyword>Neuroblastoma</keyword>
  <keyword>Malignant rhabdoid tumor</keyword>
  <keyword>Rhabdomyosarcoma</keyword>
  <keyword>Osteosarcoma</keyword>
  <keyword>Brain tumor</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Malignant glioma</keyword>
  <keyword>Diffuse intrinsic pontine glioma</keyword>
  <keyword>Medulloblastoma</keyword>
  <keyword>Ependymoma</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>High-grade glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

